Both in Biotechnology
enGene Therapeutics vs Neumora Therapeutics
Over the past year ENGN returned −76.6% and NMRA returned −81.0%; their daily moves had a correlation of 0.15.
ENGN −76.6% NMRA −81.0%Growth of $1, one year, split-adjusted
| Metric | ENGN | NMRA |
|---|---|---|
| Price | $1.62 | $0.5709 |
| Market cap | $108.6M | $107.3M |
| Today | +11.72% | +15.17% |
| 1 month | −13.4% | +8.7% |
| 6 months | −79.5% | −75.2% |
| Year to date | −82.1% | −68.1% |
| 1 year | −77.5% | −81.1% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $241.0M | $63.9M |
| Dividend yield | — | — |
| Volatility (60d) | 57.4% | 126.3% |
| Short % of float | 3.4% | 6.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).